GlobeNewswire

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

Share

Nightstar acquisition further bolsters Biogen’s pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programs

CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. The total transaction value was approximately $800 million, after taking into account expected transaction expenses and cash at closing. NST’s common stock will no longer be listed for trading on the Nasdaq Global Select Market.

NST’s lead asset is NSR-REP1 for the treatment of choroideremia (CHM), a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. CHM primarily affects males and is caused by loss of function in the CHM gene which encodes the Rab escort protein-1 (REP-1). Initially, patients with CHM experience poor night vision, and over time progressive visual loss ultimately leads to complete blindness.

NSR-RPGR is NST’s second clinical program for the treatment of X-linked retinitis pigmentosa (XLRP), which is also a rare inherited retinal disease primarily affecting males with no approved treatments. XLRP is characterized by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene leading to a lack of active protein transport in photoreceptors. This abnormality leads to loss of photoreceptor cells, resulting in retinal dysfunction by adolescence and early adulthood, progressing to legal blindness when patients reach their 40s.

“Today marks a significant achievement for Biogen,” said Michel Vounatsos, Biogen’s Chief Executive Officer. “The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities. We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

Goldman, Sachs & Co. acted as financial advisor to Biogen, and Ropes & Gray LLP acted as legal counsel.

Centerview Partners acted as financial advisor to NST, and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal counsel.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at  www.biogen.com . To learn more, please visit  www.biogen.com  and follow us on social media –  Twitter , LinkedIn Facebook YouTube .

Biogen Safe Harbor

This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits and results that may be achieved through the acquisition; risks and uncertainties associated with drug development and commercialization; the potential benefits, safety and efficacy of investigational therapies, including NSR-REP1 and NSR-RPGR; our strategy and plans; the potential of our commercial business and pipeline programs, including NSR-REP1 and NSR-RPGR; and our capital allocation and investment strategy. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: uncertainty as to whether the anticipated benefits of the acquisition can be achieved; our ability to successfully integrate NST’s operations and employees; risks of unexpected costs or delays; uncertainty of success in the development and potential commercialization of NSR-REP1 and NSR-RPGR, which may be impacted by, among other things, the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of NSR-REP1 and NSR-RPGR; we may encounter other unexpected hurdles, which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions or failure to protect intellectual property and other proprietary rights; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risks factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements are based on our current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

MEDIA CONTACT:

David Caouette
+ 1 617 679 4945
public.affairs@biogen.com
INVESTOR CONTACT:

Matt Calistri
+1 781 464 2442
IR@biogen.com

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer29.5.2020 12:03:00 CESTPress release

·Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy in Europe Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under conditional marketing authorisation for Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The CHMP has also recommended Rozlytrek for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with RO

RESULT OF RIKSBANK REVERSED AUCTION SEK BONDS MAY 29, 202029.5.2020 10:09:32 CESTPress release

Auction date2020-05-29Loan1061Coupon0.75 %ISIN-codeSE0011281922Maturity2029-11-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln3,825Volume bought, SEK mln1,000Number of bids17Number of accepted bids2Average yield-0.040 %Lowest accepted yield-0.040 %Highest yield-0.039 %% accepted at lowest yield 90.00 Auction date 2020-05-29 Loan 1062 Coupon 0.125 % ISIN-code SE0013935319 Maturity 2031-05-12 Tendered volume, SEK mln 1,000 +/- 250 Volume offered, SEK mln 4,150 Volume bought, SEK mln 1,000 Number of bids 15 Number of accepted bids 4 Average yield 0.093 % Lowest accepted yield 0.089 % Highest yield 0.096 % % accepted at lowest yield 100.00

Pawel Wyszynski new Head of Investor Relations at SEB29.5.2020 09:00:00 CESTPress release

Press release Stockholm 29 May 2020 Pawel Wyszynski has been appointed new Head of Investor Relations at SEB and will assume his position on 7 September 2020. Prior to joining SEB, Pawel Wyszynski has held the position as Director of Shareholder Relations at EQT and he has a solid background as Equity Analyst at Nordea, Danske Bank and Crédit Agricole Cheuvreux. The present Head of Investor Relations, Christoffer Geijer, will join the management team of SEB Investment Management to lead the effort to enhance the distribution of SEB IM’s product offering. For further information, please contact Frank Hojem, Head of Corporate Communication +46(0)8 763 99 47 frank.hojem@seb.se SEB is a leading Nordic financial services group with a strong belief that entrepreneurial minds and innovative companies are key in creating a better world. SEB takes a long-term perspective and supports its customers in good times and bad. In Sweden and the Baltic countries, SEB offers financial advice and a wide

Pawel Wyszynski ny chef för Investor Relations på SEB29.5.2020 09:00:00 CESTPressemelding

Pressmeddelande Stockholm 29 maj 2020 Pawel Wyszynski har blivit utnämnd till ny chef för Investor Relations på SEB och tillträder sin tjänst den 7 september 2020. Pawel Wyszynski har tidigare varit chef för Shareholder Relations på EQT och har en gedigen bakgrund som aktieanalytiker på Nordea, Danske Bank och Crédit Agricole Cheuvreux. Den nuvarande chefen för Investor Relations, Christoffer Geijer, kommer att tillträda en tjänst inom ledningen för SEB Investment Management, där han kommer att leda arbetet med att optimera distributionen av SEB IM:s produktutbud. För mer information kontakta Frank Hojem, chef Corporate Communication 08-763 9947 frank.hojem@seb.se SEB är en ledande nordisk finansiell koncern. Vi tror starkt på att entreprenöriellt tänkande och innovativa företag behövs för att skapa en bättre värld, och med ett långsiktigt perspektiv stöttar vi våra kunder i både med- och motgång. I Sverige och i de baltiska länderna erbjuder vi ett stort spann av finansiella tjänster